Interestingly, it has been demonstrated that PLX4720—a BRAF inhibitor used to treat BRAF-mutated melanoma cells—leads to the activation of melanoma associated fibroblasts causing ECM remodelling, which triggers increased integrin β1/FAK/Scr signalling in melanoma cells. This evidence concerns the gene BRAF and melanoma.